Stockholders' Equity - Additional Information (Details)

v3.24.3

Stockholders' Equity - Additional Information (Details) - USD ($)												3 Months Ended					9 Months Ended
	Apr. 25, 2024	Mar. 28, 2024	Mar. 14, 2024	Nov. 17, 2023	Nov. 15, 2023	Nov. 13, 2023	Nov. 09, 2023	Sep. 28, 2023	May 25, 2023	Aug. 03, 2022	Aug. 01, 2022	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	May 31, 2024	May 15, 2024	Mar. 25, 2024	Feb. 14, 2024	Dec. 31, 2023	Dec. 31, 2021
Subsidiary or Equity Method Investee [Line Items]
Common stock, shares authorized											70,000,000	70,000,000					70,000,000						70,000,000
Preferred stock, shares authorized											30,000,000	30,000,000					30,000,000						30,000,000
Common stock, par value												$ 0.0001					$ 0.0001						$ 0.0001
Warrants exercise price, per share											$ 6.25
Stock options outstanding												9,389,527					9,389,527						7,750,152
Fair value assumptions, contractual term																	7 years
Exercise price percentage																	110.00%
Percentage of shares granted																	10.00%
Warrants and rights exercisable period											Jan. 23, 2023
Class of warrant or right date from which warrants or rights expire											Jul. 27, 2027
Loss (gain) on remeasurement of warrant liability												$ (1,331,286)			$ (18,193)		$ 8,007,505	$ (141,934)
Share Repurchase Program
Subsidiary or Equity Method Investee [Line Items]
Common stock, par value								$ 0.0001
Share repurchase program expiration period								2024-09
Shares repurchased																	0
Black-Sholes Method
Subsidiary or Equity Method Investee [Line Items]
Risk free interest rate										2.82%
Volatility rate										77.50%
Fair value assumptions, contractual term										5 years
Warrants										$ 343,735
Maximum
Subsidiary or Equity Method Investee [Line Items]
Fair value assumptions, contractual term																	10 years
Warrants to purchase aggregate of common stock											100,000
Maximum | Share Repurchase Program
Subsidiary or Equity Method Investee [Line Items]
Share repurchase authorized amount								$ 800,000
2018 Stock Option Plan
Subsidiary or Equity Method Investee [Line Items]
Common stock reserved for issuance												0					0
Stock options outstanding												1,833,857					1,833,857
Amended and Restated 2020 Equity Incentive Plan
Subsidiary or Equity Method Investee [Line Items]
Common stock reserved for issuance												0					0
Stock options outstanding												3,503,589					3,503,589
2021 Equity Incentive Plan
Subsidiary or Equity Method Investee [Line Items]
Common stock reserved for issuance											1,909,518	2,483,927					2,483,927						2,838,668	1,956,993
Stock options outstanding												4,052,081					4,052,081
Percentage of increase in stock outstanding fully diluted									10.00%
IPO | Black-Sholes Method
Subsidiary or Equity Method Investee [Line Items]
Warrants												$ 140,963					$ 140,963						$ 40,211
Loss (gain) on remeasurement of warrant liability												$ (68,646)			$ (18,193)		$ 100,752	(141,934)
Overallotment Option | Maximum
Subsidiary or Equity Method Investee [Line Items]
Class of warrant or right additional purchase aggregate of common stock										15,000
At The Market Offering Agreement | H.C. Wainwright and Co., LLC
Subsidiary or Equity Method Investee [Line Items]
Common stock, par value																						$ 0.0001
Number of common stock Issued and sold																	2,700,482
Common stock per share												$ 3.16					$ 3.16
Gross proceeds from sale of common stock																	$ 8,522,666
Commissions paid																	255,680
Net proceeds from common stock																	8,266,986
Percentage of gross proceeds of offerings																				3.00%
Private Placement
Subsidiary or Equity Method Investee [Line Items]
Common stock per share	$ 2.034	$ 2.295	$ 1.17
Aggregate purchase price	$ 1,000,000	$ 1,330,000	$ 2,920,000
Warrants exercise price, per share			$ 1.3
Warrants and rights exercisable period			Sep. 14, 2024
Class of warrant or right date from which warrants or rights expire	Oct. 25, 2029	Sep. 28, 2029	Sep. 14, 2029
Warrants																			$ 5,089,063
Loss (gain) on remeasurement of warrant liability												$ 0					3,039,463
Private Placement | Black-Sholes Method
Subsidiary or Equity Method Investee [Line Items]
Risk free interest rate			4.20%
Volatility rate			95.00%
Fair value assumptions, contractual term			5 years 6 months
Warrants			$ 2,049,600
Private Placement | Amendment Of Warrant Agreements
Subsidiary or Equity Method Investee [Line Items]
Warrants																			$ 437,031
Private Placement Offering 1
Subsidiary or Equity Method Investee [Line Items]
Gross proceeds from sale of common stock																	$ 2,920,696
Private Placement Offering 1 | Amendment Of Warrant Agreements
Subsidiary or Equity Method Investee [Line Items]
Remaining warrant liability												141,612					141,612
Warrants												$ 294,750					$ 294,750						0
Loss (gain) on remeasurement of warrant liability												(76,921)					3,493
Private Placement Offering
Subsidiary or Equity Method Investee [Line Items]
Warrants to purchase aggregate of common stock																			437,031
Warrants and rights exercisable period	Oct. 25, 2024	Sep. 28, 2024
Class of warrant or right date from which warrants or rights expire	Oct. 25, 2029	Sep. 28, 2029
Private Placement Offering | Black-Sholes Method
Subsidiary or Equity Method Investee [Line Items]
Risk free interest rate		4.20%
Volatility rate		95.00%
Fair value assumptions, contractual term		5 years 6 months
Warrants		$ 1,190,111
Private Placement Offering | Amendment Of Warrant Agreements
Subsidiary or Equity Method Investee [Line Items]
Warrants												1,011,562					1,011,562		$ 1,011,562
Loss (gain) on remeasurement of warrant liability												0					112,708
Private Placement Offering April 2024
Subsidiary or Equity Method Investee [Line Items]
Warrants																			$ 769,671
Loss (gain) on remeasurement of warrant liability												0					91,752
Registered Direct Offering
Subsidiary or Equity Method Investee [Line Items]
Warrants exercise price, per share				$ 1.86	$ 2.06
Risk free interest rate				3.85%	3.84%
Volatility rate				90.00%	90.00%
Fair value assumptions, contractual term				5 years 4 months 17 days	4 years 10 months 17 days
Warrants to purchase aggregate of common stock					169,697
Warrants and rights exercisable period					Nov. 15, 2023
Class of warrant or right date from which warrants or rights expire					Nov. 15, 2028
Warrants				$ 1,903,915	$ 123,811							344,198					344,198						123,811
Loss (gain) on remeasurement of warrant liability												(118,277)					$ 220,387
Registered Direct Offering | Black-Sholes Method
Subsidiary or Equity Method Investee [Line Items]
Number of common stock Issued and sold																	458,726
Issuance of common shares upon cashless exercise of warrants, shares																	909,091
Warrants				2,815,970								3,235,441					$ 3,235,441						1,903,915
Increase in equity on exercise of warrant liability				$ 2,815,970
Loss (gain) on remeasurement of warrant liability												$ (1,067,442)					4,147,496
Registered Direct Offering | Maximum
Subsidiary or Equity Method Investee [Line Items]
Warrants to purchase aggregate of common stock				2,424,243
Directors | Private Placement | Black-Sholes Method
Subsidiary or Equity Method Investee [Line Items]
Risk free interest rate			4.20%
Volatility rate			95.00%
Fair value assumptions, contractual term			5 years 6 months
Warrants			$ 230,685
Directors | Private Placement Offering | Black-Sholes Method
Subsidiary or Equity Method Investee [Line Items]
Risk free interest rate	4.70%
Volatility rate	95.00%
Fair value assumptions, contractual term	5 years 6 months
Warrants	$ 346,606
Common Stock | Follow-on Offering
Subsidiary or Equity Method Investee [Line Items]
Number of common stock Issued and sold																2,555,500
Common Stock | At-the-Market Equity Offering
Subsidiary or Equity Method Investee [Line Items]
Number of common stock Issued and sold												177,606	2,015,122	507,754
Common Stock | At The Market Offering Agreement | Maximum | H.C. Wainwright and Co., LLC
Subsidiary or Equity Method Investee [Line Items]
Aggregate offering price																				$ 11,280,000	$ 4,950,000	$ 1,445,000
Common Stock | Private Placement
Subsidiary or Equity Method Investee [Line Items]
Number of common stock Issued and sold	494,096	578,643	2,496,318
Common Stock | Private Placement Offering 1
Subsidiary or Equity Method Investee [Line Items]
Number of common stock Issued and sold														2,496,318
Common Stock | Directors | 2021 Equity Incentive Plan
Subsidiary or Equity Method Investee [Line Items]
Number of common stock Issued and sold	167,157
Common Stock | Directors | Private Placement Offering | 2021 Equity Incentive Plan
Subsidiary or Equity Method Investee [Line Items]
Number of common stock Issued and sold			452,731
Common Stock | Non-Affiliated Investors | Private Placement Offering
Subsidiary or Equity Method Investee [Line Items]
Number of common stock Issued and sold	326,939		2,043,587
Investor Warrants | Private Placement
Subsidiary or Equity Method Investee [Line Items]
Number of common stock Issued and sold	494,096	578,643	2,496,318
Common stock per share	$ 2.26	$ 2.55	$ 1.3
Investor Warrants | Private Placement Offering
Subsidiary or Equity Method Investee [Line Items]
Number of common stock Issued and sold	494,096	578,643
Common stock per share	$ 2.26																					$ 2.55
Oustside Investors Warrants | Private Placement Offering | Black-Sholes Method
Subsidiary or Equity Method Investee [Line Items]
Risk free interest rate	4.70%
Volatility rate	95.00%
Fair value assumptions, contractual term	5 years 6 months
Warrants	$ 677,919
Restricted Stock Awards
Subsidiary or Equity Method Investee [Line Items]
Stock compensation expense																	$ 111,500	$ 682,962
Shares granted																	47,102	248,969
Unvested shares												0			0		0	0
Alumni Capital LP
Subsidiary or Equity Method Investee [Line Items]
Warrants exercise price, per share							$ 2.09
Risk free interest rate							3.93%
Volatility rate							90.00%
Fair value assumptions, contractual term							3 years 10 months 13 days
Warrants and rights exercisable period							Nov. 10, 2023
Class of warrant or right date from which warrants or rights expire							Nov. 10, 2027
Warrants							$ 84,251
Warrant shares vested						131,578
Alumni Capital LP | Laidlaw & Company Ltd
Subsidiary or Equity Method Investee [Line Items]
Warrant fee paid in cash							$ 13,750
Warrants and rights exercisable period							May 22, 2024
Issuance of common shares upon cashless exercise of warrants, shares						54,976
Warrants							$ 375,705					$ 0					$ 0						$ 84,251
Loss (gain) on remeasurement of warrant liability												$ 0					$ 291,454
Alumni Capital LP | Maximum
Subsidiary or Equity Method Investee [Line Items]
Warrants to purchase aggregate of common stock							239,234